Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT

Meng, Guangqiang; Wang, Jingshi; Wang, Xinkai; Wang, Yini; Wang, Zhao

doi:10.1007/s00277-019-03864-y

Cited by 14 publications

(32 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[70]. Hemophagocytic lymphohistiocytosis, a rare secondary disease triggered by viral infection or autoimmune disease, in which a hyper-activated immune response may causesevere complications; ruxolitinib has been shown to suppress cytokine levels and the JAK/STAT pathway in Epstein-Barr Virus (EBV)-associated hemophagocytic lymphohistiocytosis [71].…”

Section: Immunosuppressionmentioning

confidence: 99%

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

Bağca

Avcı

2020

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

Section: Immunosuppressionmentioning

confidence: 99%

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

Bağca

Avcı

2020

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

show abstract

“…Allogeneic hematopoietic stem cell transplantation may be the best treatment for recurrent EBV‐HLH 56 . It is likewise a potential treatment option for patients with r/r‐HLH 57 . Acute graft‐versus‐host disease (GVHD) is a serious complication of HSCT, and it is the main cause of nonrecurring mortality after HSCT 57 .…”

Section: Complicationsmentioning

confidence: 99%

“…It is likewise a potential treatment option for patients with r/r‐HLH 57 . Acute graft‐versus‐host disease (GVHD) is a serious complication of HSCT, and it is the main cause of nonrecurring mortality after HSCT 57 . Initially, the incidence of transplant‐related complications was high, which was the principle obstacle to the wider adoption of the protocol 56 .…”

Section: Complicationsmentioning

confidence: 99%

Serious consequences of Epstein‐Barr virus infection: Hemophagocytic lymphohistocytosis

Guo

Guan

2021

Int J Lab Hematology

View full text Add to dashboard Cite

Human is the host of the Epstein‐Barr virus (EBV) especially in childhood and adolescence. Most of them are asymptomatic infection and self‐limiting. However, for those patients who suffer from immune dysfunction, EBV infection will be life‐threatening. Epstein‐Barr virus‐associated hemophagocytic lymphohistocytosis (EBV‐HLH) is one of the severe effects. The diagnosis and differential diagnosis of EBV‐HLH and other EBV infectious diseases are mentioned in this paper. The molecular biology mechanism and complications of EBV‐HLH are equally briefly presented. It also provides a practical method for the genetic diagnosis of such diseases and the differential diagnosis with other human immunodeficiency diseases for medical scientists in routine clinical practice.

show abstract

“…Ruxolitinib is a Janus-associated kinase (JAK)1/2 inhibitor approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of polycythemia vera and myelofibrosis. 22 It is also a promising option in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation 23 or secondary hemophagocytic lymphohistiocytosis 24 by targeting the deleterious effects of aberrant host inflammatory response. Anemia was the most common adverse event in patients receiving ruxolitinib though most anemia events were mild to moderate in severity.…”

mentioning

confidence: 99%

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Cao

Wei

Zou

et al. 2020

Journal of Allergy and Clinical Immunology

411

421

View full text Add to dashboard Cite

Background: Accumulating evidence proposed Janus-associated kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation. Objective: This study evaluated the efficacy and safety of ruxolitinib, a JAK1/2 inhibitor, for coronavirus disease 2019. Methods: We conducted a prospective, multicenter, single-blind, randomized controlled phase II trial involving patients with severe coronavirus disease 2019. Results: Forty-three patients were randomly assigned (1:1) to receive ruxolitinib plus standard-of-care treatment (22 patients) or placebo based on standard-of-care treatment (21 patients). After exclusion of 2 patients (1 ineligible, 1 consent withdrawn) from the ruxolitinib group, 20 patients in the intervention group and 21 patients in the control group were included in the study. Treatment with ruxolitinib plus standard-of-care was not associated with significantly accelerated clinical improvement in severe patients with coronavirus disease 2019, although ruxolitinib recipients had a numerically faster clinical improvement. Eighteen (90%) patients from the ruxolitinib group showed computed tomography improvement at day 14 compared with 13 (61.9%) patients from the control group (P 5 .0495). Three patients in the control group died of respiratory failure, with 14.3% overall mortality at day 28; no patients died in the ruxolitinib group. Ruxolitinib was well tolerated with low toxicities and no new safety signals. Levels of 7 cytokines were significantly decreased in the ruxolitinib group in comparison to the control group. Conclusions: Although no statistical difference was observed, ruxolitinib recipients had a numerically faster clinical improvement. Significant chest computed tomography improvement, a faster recovery from lymphopenia, and favorable side-effect profile in the ruxolitinib group were encouraging and informative to future trials to test efficacy of ruxolitinib in a larger population. (

show abstract

Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT

Cited by 14 publications

References 23 publications

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

Serious consequences of Epstein‐Barr virus infection: Hemophagocytic lymphohistocytosis

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Contact Info

Product

Resources

About